The PharmaMarketing Summit 2027 will take place from January 21 to January 22 at the Four Seasons...
PharmaMarketing Summit 2027 Tackles AI, Market Access & Specialty
Pharmaceutical marketing teams are navigating an increasingly complex set of priorities at once. AI-driven personalization, specialty and rare disease commercialization, payer-focused market access requirements, and the demand for more equitable, data-informed patient engagement are no longer separate workstreams. They are converging, and commercial leaders are being asked to manage them simultaneously with limited internal alignment across functions.
The PharmaMarketing Summit 2027, taking place January 21 to 22 at the Four Seasons Hotel Westlake Village in California, has been designed around this reality. Rather than treating these themes as isolated topics, the Summit brings them into a single, structured forum where marketing, access, and digital leaders can address how these priorities intersect in practice.
Several trends shaping this year's agenda reflect where the industry is currently focused:
AI and omnichannel engagement
Pharma marketers are under pressure to personalize HCP and patient engagement without losing compliance oversight. The Summit will examine how companies are operationalizing AI tools within existing commercial infrastructure, rather than treating them as standalone pilots.
Specialty and rare disease commercialization
As more pipelines shift toward specialty and rare disease indications, commercial teams face smaller, more defined patient populations and the need for advocacy-driven engagement models that differ significantly from mass-market approaches.
Market access as a marketing function
Pricing, access, and value communication are increasingly being managed in direct coordination with marketing teams rather than as a separate downstream process, requiring closer alignment between these functions earlier in the commercial lifecycle.
Health equity and inclusive data strategy
Building engagement models that account for diverse patient populations has moved from a compliance consideration to a core input in campaign design and measurement.
By addressing these themes together rather than in separate conferences, the Summit allows attendees to see how decisions in one area, such as AI adoption, directly affect others, such as access strategy or health equity commitments. This unified setting is intended to reflect how commercial decisions are actually made inside pharmaceutical organizations today.
